Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2025 08:30 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program

VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response...
January 30, 2025 12:16 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange

VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel...
January 29, 2025 08:30 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics to Participate in BioInnovate UBC Annual Conference

VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company advancing innovative cancer therapies through artificial...
January 22, 2025 07:30 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Comments on $500 Billion AI Infrastructure Investment and Its Implications for Healthcare Innovation

VANCOUVER, British Columbia, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented...
January 13, 2025 08:30 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI

VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel...
January 06, 2025 08:30 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation

VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel...
January 03, 2025 16:30 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week

VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics, Inc. (TSX: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel...
December 19, 2024 07:55 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025

VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical company focused on the development of new...
December 17, 2024 21:55 ET | Source: Rakovina Therapeutics Inc

Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture...
December 13, 2024 18:50 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina Therapeutics”) a biopharmaceutical company committed to...